个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：
Tan, Fenlai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Gu, Aiqin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Yiping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Jiao, Shun Chang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Chang-Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; He, Jintao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Jia, Xueke[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Li[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Peng, Jiewen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wu, Meina[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ying, Kejing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Junye[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ma, Kewei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Zhang, Shucai[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; You, Changxuan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Ding, Lieming[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wang, Yinxiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Shen, Haijiao[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Wan, Jiang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ; Sun, Yan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16] ;
机构： [1]Zhejiang Beta Pharma Inc, Hangzhou, Zhejiang, Peoples R China [2]Shandong Prov Chest Hosp, Shanghai, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [4]Gen Hosp PLA, Beijing, Peoples R China [5]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [6]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [7]Baoding Hengxing Med Integrat Hosp, Baoding, Peoples R China [8]Perking Union Med Hosp, Beijing, Peoples R China [9]Zhongshan Peoples Hosp, Zhongshan, Peoples R China [10]Beijing Canc Hosp, Beijing, Peoples R China [11]Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China [12]Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China [13]Jilin Univ, Bethune Hosp 1, Changchun 130023, Peoples R China [14]Beijing Chest Hosp, Beijing, Peoples R China [15]China Nanfang Hosp, Guangzhou, Guangdong, Peoples R China [16]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China
出处：
DOI： 10.1200/jco.2013.31.15_suppl.e19161
ISSN：
语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2013]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
JCR分区：
出版当年[2013]版：
Q1 ONCOLOGY
最新[2023]版：
Q1 ONCOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2013版] 出版当年五年平均 出版前一年[2012版] 出版后一年[2014版]

第一作者：
第一作者机构： [1]Zhejiang Beta Pharma Inc, Hangzhou, Zhejiang, Peoples R China [2]Shandong Prov Chest Hosp, Shanghai, Peoples R China [3]Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China [4]Gen Hosp PLA, Beijing, Peoples R China [5]Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China [6]Sichuan Canc Hosp & Inst, Chengdu, Peoples R China [7]Baoding Hengxing Med Integrat Hosp, Baoding, Peoples R China [8]Perking Union Med Hosp, Beijing, Peoples R China [9]Zhongshan Peoples Hosp, Zhongshan, Peoples R China [10]Beijing Canc Hosp, Beijing, Peoples R China [11]Sir Run Run Shaw Hosp, Hangzhou, Zhejiang, Peoples R China [12]Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China [13]Jilin Univ, Bethune Hosp 1, Changchun 130023, Peoples R China [14]Beijing Chest Hosp, Beijing, Peoples R China [15]China Nanfang Hosp, Guangzhou, Guangdong, Peoples R China [16]Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China
推荐引用方式(GB/T 7714)：
Tan Fenlai,Gu Aiqin,Zhang Yiping,et al.Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study[J].JOURNAL OF CLINICAL ONCOLOGY.2013,31(15):doi:10.1200/jco.2013.31.15_suppl.e19161.
APA：
Tan, Fenlai,Gu, Aiqin,Zhang, Yiping,Jiao, Shun Chang,Wang, Chang-Li...&Sun, Yan.(2013).Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.JOURNAL OF CLINICAL ONCOLOGY,31,(15)
MLA：
Tan, Fenlai,et al."Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study".JOURNAL OF CLINICAL ONCOLOGY 31..15(2013)

资源点击量：43378 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号